OMMAYA ARTIFICIAL ORGAN FOR ISLET TRANSPLANTATION

OMMAYA 胰岛移植人工器官

• 批准号: 2146475
• 负责人: AYUB K OMMAYA
• 金额: $ 7.35万
• 依托单位: CYBORGAN, INC.
• 依托单位国家: 美国
• 财政年份: 1994
• 资助国家: 美国
• 起止时间: 1994-08-01 至 1995-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2146475
• 关键词: artificial endocrine pancreas; cerebrospinal fluid; dogs; drug delivery systems; endocrine transplantation; nervous system disorder; neurotrophic factors; pancreatic islets; xenotransplantation

The proposed research seeks to establish the feasibility of a macroencapsulation device containing islet cells for the treatment of insulin dependent diabetes. The device is a direct application of the spinal fluid flow driven artificial organ invented by the P.I. (U.S. Patent No. 5,222,982). Preliminary experiments in vitro and in vivo (canine model) indicate that xenograft islet cells are immune protected while living in CSF, CSF glucose follows serum glucose, islets in CSF release insulin with lag times less than 25 minutes and diabetic dogs display decrease of serum glucose and insulin requirements under short- term observation. These data are presented in the body of our proposal. We seek to extend and complete these observations for longer periods of treatment with larger numbers of islets and confirm the immune protection including the lack of significant host sensitization to proteins associated with the xenogenic islets. The work will be carried on as before using a CRADA with Dr. Illani Atwater at NIDDK/NIH and with Dr. J. Bacher at NCRR/NIH.

拟议的研究旨在确定a的可行性